Nashua, NH, USA - February 24, 2026 – Consumer health company AcuDart Health has announced that its Tick-Borne Disease (TBD) test panel—which detects Lyme disease, Tick-Borne Relapsing Fever (TBRF), Bartonellosis, and Babesiosis—is now available for order worldwide. Launched in the United States in August 2024, the test is now accessible to patients in over 50 countries with no doctor authorization required. And, for a limited time, customers can save $100 by using the code HEALTHY26.
Lyme disease is caused by the bacterium Borrelia burgdorferi, transmitted by deer ticks. Symptoms include fever, headache, fatigue, chills, and joint or muscle pain. Lyme disease is increasingly recognized as one of the fastest-growing vector-borne illnesses around the world, driven by environmental, ecological, and public health factors. In the U.S., reported cases have risen significantly over the past few decades, with an estimated 476,000 Americans diagnosed and treated each year. Globally, research suggests Lyme disease prevalence has also increased, with studies indicating a rise in infections in Europe, Asia, and Australia, partly due to climate change, changing land use, and growing populations of deer and rodents that carry ticks. Warmer temperatures and milder winters are allowing ticks to survive longer, expand into new regions, and remain active for more months of the year, increasing the risk of exposure.
AcuDart Offers Superior Accuracy
Low diagnostic sensitivity has challenged tick-borne disease testing for decades, contributing to missed or delayed diagnoses for many patients. AcuDart testing is designed to improve detection by assessing immune responses to a broader range of disease-causing species. For Lyme disease specifically, while many conventional tests measure antibodies to only one or two Borreliaspecies, AcuDart evaluates antibodies to nine Lyme-associated species. By expanding species coverage, the test aims to enhance detection capability compared to traditional two-tier testing protocols recommended by the CDC and commonly used commercial testing options. This broader approach helps identify cases that could otherwise go undetected.
Diagnosis of any TBD based on clinical grounds is very challenging because symptoms can mimic many other diseases. These diseases can also affect any organ of the body, including the brain and nervous system, muscles and joints, and the heart. Only with accurate and reliable testing can patients determine if they have a TBD.
Key features of the AcuDart tests
- Screens for 19 markers across Lyme disease, TBRF, Babesiosis, and Bartonellosis
- Completed at home
- Fast and free FedEx shipping both ways in USA and Canada
- No doctor authorization required
- Can be purchased for others
- Five year shelf life so you can stock up
- Detects antibodies to more species than competing tests
